In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan

被引:26
作者
Cheng, NC
Hsueh, PR
Liu, YC
Shyr, JM
Huang, WK
Teng, LJ
Liu, CY
机构
[1] Natl Taiwan Univ, Coll Med, Dept Lab Med, Taipei, Taiwan
[2] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan
[3] Taipei Vet Gen Hosp, Dept Internal Med, Taipei, Taiwan
[4] Kaohsiung Vet Gen Hosp, Dept Clin Pathol, Kaohsiung, Taiwan
[5] Kaohsiung Vet Gen Hosp, Dept Internal Med, Kaohsiung, Taiwan
[6] Taichung Vet Gen Hosp, Dept Clin Pathol, Taichung, Taiwan
[7] Natl Taiwan Univ Hosp, Coll Med, Sch Med Technol, Taipei 10764, Taiwan
关键词
D O I
10.1089/mdr.2005.11.330
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This study evaluated the in vitro activities of tigecycline, ertapenem, isepamicin, and other comparators against 861 bacterial isolates recovered from patients treated in three major teaching hospitals in 2003. MICs to antimicrobial agents were determined by the agar dilution method. High rates of oxacillin resistance (58%) in Staphylococcus aureus (60 isolates), and vancomycin resistance (21%) and quinupristin-dalfopristin nonsusceptibility (39%) in Enterococcus faecium (34 isolates) were found. Carbapenems had excellent in vitro activities (>= 98% susceptibility) against the 419 isolates of Enterobacteriaceae, with the MIC50 and MIC90 of imipenem, meropenem, and ertapenem being 0.25 and 4 mg/L, 0.03 and 0.12 mg/L, and 0.03 and 0.5 mg/L, respectively. For, Pseudomonas aeruginosa (74 isolates) and Burkholderia cepacia (21 isolates), meropenem (MIC90, 0.25, 2, and 4 mg/L, respectively) had better in vitro activities than imipenem (MIC90, 8, 4, and 32 mg/L, respectively) and ertapenem (MIC90, 0.5, > 32, and 32 mg/L, respectively). Isepamicin had a similar activity with amikacin against all Enterobacteriaceae, Pseudomonas aeruginosa, B. cepacia, and Acinetobacter baumannii, except for C. freundii isolates in which isepamicin had an eight-fold activity better than amikacin. Tigecycline had excellent in vitro activities against all isolates tested (MIC90, :51 mg/L) including 14 pandrugresistant A. baumannii isolates (MICs, 1-4 mg/L), except for Proteus mirabilis (59 isolates; MIC90, 8 mg/L), Bacteroides fragilis (60 isolates; MIC90, 8 mg/L), P. aeruginosa (MIC90, 16 mg/L), and B. cepacia (21 isolates; MIC90, 16 mg/L). Tigecycline, carbapenems, and isepamicin exhibited better or comparable in vitro activities against a wide spectrum of commonly encountered bacteria than other comparator antimicrobials and may represent therapeutic options for infections due to multidrug-resistant pathogens.
引用
收藏
页码:330 / 341
页数:12
相关论文
共 35 条
[1]  
[Anonymous], 2004, M100S14 NAT COMM CLI
[2]   Antimicrobial resistance in isolates from inpatients and outpatients in the united states: Increasing importance of the intensive care unit [J].
Archibald, L ;
Phillips, L ;
Monnet, D ;
McGowan, JE ;
Tenover, F ;
Gaynes, R .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (02) :211-215
[3]   In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain [J].
Betriu, C ;
Rodríguez-Avial, I ;
Sánchez, BA ;
Gómez, M ;
Alvarez, J ;
Picazo, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :892-895
[4]   In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria [J].
Boucher, HW ;
Wennersten, CB ;
Eliopoulos, GM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2225-2229
[5]   In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides [J].
Cercenado, E ;
Cercenado, S ;
Gómez, JA ;
Bouza, E .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (01) :138-139
[6]   Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1 [J].
Dean, CR ;
Visalli, MA ;
Projan, SJ ;
Sum, PE ;
Bradford, PA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (03) :972-978
[7]  
Edlund C, 2000, CLIN MICROBIOL INFEC, V6, P158
[8]  
Fluit AC, 2001, EUR J CLIN MICROBIOL, V20, P617
[9]   Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2 [J].
Fridkin, SK ;
Steward, CD ;
Edwards, JR ;
Pryor, ER ;
McGowan, JE ;
Archibald, LK ;
Gaynes, RP ;
Tenover, FC .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (02) :245-252
[10]   In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections [J].
Fritsche, TR ;
Kirby, JT ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 49 (03) :201-209